Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L J Helman

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Clinical Orthopaedics and Related Research|May 16, 2000
Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapyC Mackall, J Berzofsky, L J Helman
Cancer Research|November 1, 1994
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2T Kalebic, M Tsokos, L J Helman
International Journal of Cancer|November 27, 1996
Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470T Kalebic, M Tsokos, L J Helman
The Journal of Clinical Investigation|July 1, 1994
Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcomaS Zhan, D N Shapiro, L J Helman
Oncogene|December 21, 1995
Loss of imprinting of IGF2 in Ewing's sarcomaS Zhan, D N Shapiro, L J Helman
Cancer Research|April 1, 1992
Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loopC P Minniti, M Maggi, L J Helman
Important Advances in Oncology|January 1, 1987
Patterns of proto-oncogene expression: a novel approach to the development of tumor markersM A Israel, L J Helman, J Miser
Annals of Internal Medicine|August 1, 1984
Thrombocytopenia and extragonadal germ-cell neoplasmL J Helman, R F Ozols, D L Longo
Experimental Cell Research|February 1, 1993
Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell lineG D Crouch, T Kalebic, M Tsokos, et al.
Sarcoma|January 1, 1997
Disruption of the MyoD/p21 Pathway in RhabdomyosarcomaM Weintraub, T Kalebic, L J Helman, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Clinical Orthopaedics and Related Research|May 16, 2000
Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapyC Mackall, J Berzofsky, L J Helman
Cancer Research|November 1, 1994
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2T Kalebic, M Tsokos, L J Helman
International Journal of Cancer|November 27, 1996
Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470T Kalebic, M Tsokos, L J Helman
The Journal of Clinical Investigation|July 1, 1994
Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcomaS Zhan, D N Shapiro, L J Helman
Oncogene|December 21, 1995
Loss of imprinting of IGF2 in Ewing's sarcomaS Zhan, D N Shapiro, L J Helman
Cancer Research|April 1, 1992
Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loopC P Minniti, M Maggi, L J Helman
Important Advances in Oncology|January 1, 1987
Patterns of proto-oncogene expression: a novel approach to the development of tumor markersM A Israel, L J Helman, J Miser
Annals of Internal Medicine|August 1, 1984
Thrombocytopenia and extragonadal germ-cell neoplasmL J Helman, R F Ozols, D L Longo
Experimental Cell Research|February 1, 1993
Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell lineG D Crouch, T Kalebic, M Tsokos, et al.
Sarcoma|January 1, 1997
Disruption of the MyoD/p21 Pathway in RhabdomyosarcomaM Weintraub, T Kalebic, L J Helman, et al.
Pageof 8